粪便微生物移植治疗活动性外周型银屑病关节炎的安全性和有效性:一项探索性随机安慰剂对照试验
该双盲、平行组、安慰剂对照、优效性试验将31例活动性外周型PsA(≥3个肿胀关节)且正在使用甲氨蝶呤的成人随机分配(1:1)至内镜引导下十二指肠FMT或假移植。26周时FMT组治疗失败率更高(60% vs 19%;RR 3.20;95%CI 1.06-9.62;p=0.018),HAQ-DI改善更差(组间差0.23;95%CI 0.02-0.44;p=0.031)利于假移植组,ACR20应答无差异(47% vs 50%)。无严重不良事件。
要点
- FMT组26周治疗失败率显著高于假移植组(60% vs 19%;RR 3.20;p=0.018)。
- HAQ-DI改善假移植组更优(组间差0.23;95%CI 0.02-0.44;p=0.031)。
- 两组ACR20应答无差异(47% vs 50%),未观察到严重不良事件。
核心结论
- 在活动性外周型PsA中,FMT未出现严重不良事件,但整体疗效劣于假移植。
研究设计与样本
- 双盲、平行组、安慰剂对照、优效性试验,97例筛查后31例随机分配(FMT组15例),30例完成26周临床评估。
主要发现
- FMT组治疗失败9例(60%),假移植组3例(19%),风险比3.20(95%CI 1.06-9.62;p=0.018)。
- HAQ-DI改善组间差0.23(95%CI 0.02-0.44;p=0.031),利于假移植组。
- ACR20应答FMT组7/15(47%),假移植组8/16(50%),无差异。
- 未观察到严重不良事件。
关键数值与推荐
- 主要疗效终点为26周内治疗失败(需强化治疗)的比例。
- 关键次要终点为26周时HAQ-DI变化和ACR20应答。
临床怎么用
- 不推荐将FMT用于活动性外周型PsA的常规治疗。
- FMT在该人群中未显示优于假移植的疗效。
局限性
- 探索性、概念验证研究,样本量小(31例随机)。
- 仅纳入正在使用甲氨蝶呤的活动性外周型PsA成人。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Although causality remains to be established, targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel treatment for inflammatory diseases. In this exploratory, proof-of-concept study, we evaluated the safety and efficacy of FMT in psoriatic arthritis (PsA). METHODS: In this double-blind, parallel-group, placebo-controlled, superiority trial, we randomly allocated (1:1) adults with active peripheral PsA (≥3 swollen joints) despite ongoing treatment with methotrexate to one gastroscopic-guided FMT or sham transplantation into the duodenum. Safety was monitored throughout the trial. The primary efficacy endpoint was the proportion of participants experiencing treatment failure (ie, needing treatment intensification) through 26 weeks. Key secondary endpoints were change in Health Assessment Questionnaire Disability Index (HAQ-DI) and American College of Rheumatology (ACR20) response at week 26. RESULTS: Of 97 screened, 31 (32%) underwent randomisation (15 allocated to FMT) and 30 (97%) completed the 26-week clinical evaluation. No serious adverse events were observed. Treatment failure occurred more frequently in the FMT group than in the sham group (9 (60%) vs 3 (19%); risk ratio, 3.20; 95% CI 1.06 to 9.62; p=0.018). Improvement in HAQ-DI differed between groups (0.07 vs 0.30) by 0.23 points (95% CI 0.02 to 0.44; p=0.031) in favour of sham. There was no difference in the proportion of ACR20 responders between groups (7 of 15 (47%) vs 8 of 16 (50%)). CONCLUSIONS: In this first preliminary, interventional randomised controlled trial of FMT in immune-mediated arthritis, we did not observe any serious adverse events. Overall, FMT appeared to be inferior to sham in treating active peripheral PsA. TRIAL REGISTRATION NUMBER: NCT03058900.
引用
- Kragsnaes MS, Kjeldsen J, Horn HC, et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. Ann Rheum Dis. 2021. PMID: 33926922. doi:10.1136/annrheumdis-2020-219511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。